Guidance for Industry: Cooperative Manufacturing Arrangements for Licensed Biologics

### 0910-0629

SUPPORTING STATEMENT

**Terms of Clearance:** None.

## **A. Justification**

1. Circumstances Making the Collection of Information Necessary

The Food and Drug Administration (FDA) is requesting an extension of Office of Management and Budget (OMB) Control No. 0910-0629 and OMB approval of the information collection provisions contained in the above-referenced guidance document. The information collection provisions are listed below:

|  |  |  |
| --- | --- | --- |
| Notification of all important proposed changes to production and facilities | Reporting | Recommends (for a divided manufacturing arrangement or shared manufacturing arrangement) that each licensed manufacturer that proposes such a change should inform the other participating licensed manufacturer(s) of the proposed change. |
| Recommends (for contract manufacturing arrangements) that the contract manufacturer should share with the license manufacturer all important proposed changes to production and facilities (including introduction of new products or at inspection). |
| Notification of results of tests and investigations regarding or possibly impacting the product | Reporting | Recommends (for contract manufacturing arrangements) that the contract manufacturer should fully inform the license manufacturer of the results of all tests and investigations regarding or possibly having an impact on the product. |
| Recommends (for contract manufacturing arrangements) that the license manufacturer should obtain assurance from the contractor that any FDA list of inspectional observations will be shared with the license manufacturer to allow evaluation of its impact on the purity, potency, and safety of the license manufacturer’s product. |
| Notification of products manufactured in a contract facility | Reporting | Recommends (for contract manufacturing arrangements) that a license manufacturer cross reference a contract manufacturing facility’s Master Files only in circumstances involving certain proprietary information of the contract manufacturer such as a list of all products manufactured in a contract facility. In this situation, the license manufacturer should be kept informed of the types or categories of all products manufactured in the contract facility. |
| Standard Operating Procedures | Recordkeeping | Reminds (for contract manufacturing arrangements) the license manufacturer that an agreement between a license manufacturer and a contract manufacturing facility normally includes procedures to regularly assess the contract manufacturing facility’s compliance with the applicable product and establishment standards. |
| Recommends (for shared manufacturing arrangements) that the final product manufacturer establish a procedure with the other participating manufacturer(s) to obtain certain information relating to the final product and post-approval obligations. |

The guidance document provides information concerning cooperative manufacturing arrangements applicable to biological products subject to licensure under section 351 of the Public Health Service Act (PHS Act) (42 U.S.C. 262). The guidance document addresses several different types of cooperative manufacturing arrangements (i.e., short supply arrangements, divided manufacturing arrangements, shared manufacturing arrangements and contract manufacturing arrangements). The guidance document describes certain reporting and recordkeeping responsibilities associated with these arrangements, including the following: (1) Notification of all important proposed changes to production and facilities, (2) notification of results of tests and investigations regarding or possibly impacting the product, (3) notification of products manufactured in a contract facility, and (4) standard operating procedures (SOPs).

2. Purpose and Use of the Information CollectionThe notifications of the requested information provides the appropriate parties with the necessary information regarding any cooperative manufacturing arrangements. The SOPs ensure that established written procedures are followed.

3. Use of Improved Information Technology and Burden Reduction

Notifications can be accomplished by e-mail, fax, or mail. Respondents can use computers, computer discs, tapes, microfiche, or microfilm, etc., in lieu of hard copy records for the purpose of maintaining records. FDA is not aware of any other improved technology to reduce the burden.

4.Efforts to Identify Duplication and Use of Similar Information

FDA is the only Agency that recommends this information. There is no similar information available from any other source.

5.Impact on Small Businesses or Other Small EntitiesThe information collection provided in the guidance applies to small as well as large facilities. Although FDA must apply the statutory and regulatory requirements to all enterprises, FDA does provide special help to small businesses. The Center for Biologics Evaluation and Research (CBER), Office of Communication, Outreach, and Development, Division of Manufacturer’s Assistance and Training, provides assistance to small businesses subject to FDA’s regulatory requirements.

6.Consequences of Collecting the Information Less Frequently

Less frequent collection of information would not provide the information that FDA needs to properly assure that biological products manufactured under cooperative manufacturing arrangements are safe, pure, and potent.

There are no technical or legal obstacles to reducing the burden.

7.Special Circumstances Relating to the Guidelines of 5 CFR 1320.5

There are no special circumstances for this collection of information.

8. Comments in Response to the Federal Register Notice and Efforts to Consult Outside theAgency

In accordance with 5 CFR 1320.8, FDA published a 60 day notice for public comment in the FEDERAL REGISTER of July 7, 2014 (79 FR 38318). No public comments were received.

9. Explanation of Any Payment or Gift to Respondents  
  
 No payment or gift was provided to respondents.

10.Assurance of Confidentiality Provided to Respondents  
  
The confidentiality of information received by FDA is consistent with the Freedom of Information Act (FOIA) and the FDA’s published regulations under 21 CFR Part 20, 21 CFR 312.130, 314.430, 601.50, 601.51, 807.95, 809.4, 812.38, and 814.122.

11.Justification for Sensitive Questions  
  
Questions of a sensitive nature are not applicable to this information collection.

12.Estimates of Annualized Burden Hours and Costs

12(a). Annualized Hour Burden Estimate

Respondents to this collection of information are licensed manufacturers, final product manufacturers, and contract manufacturers associated with cooperative manufacturing arrangements.

FDA believes that the information collection provisions mentioned in the guidance document do not create a new burden for the respondents. FDA believes the reporting and recordkeeping provisions mentioned in the guidance are part of the usual and customary business practice. Licensed manufacturers would have contractual agreements with participating licensed manufacturers, final product manufacturers, and contract manufacturers, as applicable for the type of cooperative manufacturing arrangement, to address all these information collection provisions.

For example, a list of all product types manufactured in a contract facility (e.g., contract filler for vaccines) would be part of a contractual agreement. The contract facility provides this information to FDA in a Master File and the licensed manufacturer provides a cross-reference to the Master File as part of their license application.

The guidance also refers to previously approved collections of information found in FDA regulations at 21 CFR Parts 201, 207, 211, 600, 601, 606, 607, 610, 660, 801, 803, 807, 809, and 820. The collections of information in §§ 606.121, 606.122, and 610.40 have been approved under OMB Control No. 0910-0116; § 610.2 has been approved under OMB Control No. 0910-0206; §§ 600.12(e) and 600.80 have been approved under OMB Control No. 0910-0308; §§ 601.2(a), 601.12, 610.60 through 610.65, 610.67, 660.2(c), 660.28(a) and (b), 660.35(a), 660.35(c) through (g), 660.35(i) through (m), 660.45, and 660.55(a) and (b) have been approved under OMB Control No. 0910-0338; §§ 803.20, 803.50, and 803.53 have been approved under OMB Control No. 0910-0437; and §§ 600.14 and 606.171 have been approved under OMB Control No. 0910-0458. The current good manufacturing practice regulations for finished pharmaceuticals (Part 211) have been approved under OMB Control No. 0910-0139; §§ 820.181 and 820.184 have been approved under OMB Control No. 0910-0073; the establishment registration regulations (Parts 207, 607, and 807) have been approved under OMB Control Nos. 0910-0045, 0910-0052, and 0910-0625; and the labeling regulations (Part 201, 801, and 809) have been approved under OMB Control Nos. 0910-0537, 0910-0572 and 0910-0485.

12(b). Annualized Cost Burden Estimate

There is no estimated annual cost burden eassociated with this collection of information.

13.Estimates of Other Total Annual Costs to Respondents and/or Record Keepers  
  
There are no capital, start-up, operating or maintenance costs associated with this collection of information.

14.Annualized Cost to the Federal Government

There is no estimated annual cost to the Federal Government associated with this collection of information.

15.Explanation for Program Changes or Adjustments  
  
There are no program changes or adjustments from the previous burden estimate. The collection of information in the guidance is part of usual and customary business practice.

16.Plans for Tabulation and Publication and Project Time Schedule  
  
There are no tabulated results to publish for this information collection.

17.Reason(s) Display of OMB Expiration Date is Inappropriate  
  
FDA is not seeking approval to exempt display of the expiration date of the OMB approval.

18.Exceptions to Certification for Paperwork Reduction Act Submissions  
  
There are no exceptions to the certification.